No abstract is provided for this article.
No abstract is provided for this article.
Conference Abstract| October 01 2000 Mechanism of Glucocorticoid Action: Effects on Chromatin Structure I.M. Adcock; I.M. Adcock 1Thoracic Medicine, ICSTM @ NHLI, Dovehouse Street, London SW3 6LY Search for other works by this author on: This Site PubMed Google Scholar PJ. Barnes; PJ. Barnes 1Thoracic Medicine, ICSTM @ NHLI, Dovehouse Street, London SW3 6LY Search for other works by this author on: This Site PubMed Google Scholar K. Ito K. Ito 1Thoracic Medicine, ICSTM @ NHLI, Dovehouse Street, London SW3 6LY Search for other works by this author on: This Site PubMed Google Scholar Biochem Soc Trans (2000) 28 (5): A175. https://doi.org/10.1042/bst028a175b Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Twitter LinkedIn Cite Icon Cite Get Permissions Citation I.M. Adcock, PJ. Barnes, K. Ito; Mechanism of Glucocorticoid Action: Effects on Chromatin Structure. Biochem Soc Trans 1 October 2000; 28 (5): A175. doi: https://doi.org/10.1042/bst028a175b Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest filter your search All ContentAll JournalsBiochemical Society Transactions Search Advanced Search This content is only available as a PDF. © 2000 Biochemical Society2000 Article PDF first page preview Close Modal You do not currently have access to this content.
Objectives To compare the modality of revascularization selected by the local heart team to the one recommended by the core laboratory according to the SYNTAX score 2020 amongst patients with three-vessel disease (3VD) with or without left main disease (LMCAD), who were allocated to CABG planned and solely guided by coronary computerized tomographic angiography in the FASTTRACK CABG trial. Background Personalized long term vital prognosis plays a key role in deciding between PCI and coronary artery bypass grafting (CABG) in patients with complex coronary artery disease. Methods In an interim analysis requested by the Data Safety Monitoring Board the treatment recommendations according to the SYNTAX 2020 were prospectively assessed in 57 consecutive patients (half of the planned population in this First in Man) by a core laboratory and compared to the decision of the “on site” heart team. Results According to SS-2020, the predicted absolute risk difference (ARD) in mortality between the virtual PCI treatment population and the CABG treatment group, which can be considered a virtual surrogate for the average treatment effect, increased with the duration of follow up, from 4.8±3.5% at 5 years to 8.8±5.1% at 10 years (Table 1). The ARD of less than 0% in mortality at 5-year in favour of PCI was only documented in two patients while the 55 remaining patients had a predicted survival benefit over PCI if receiving CABG. However, based on a novel threshold of equipoise (ARD <4.5%) recently validated in a contemporary registry of 3VD and LMCAD, CABG was mandatory in 26 (45.6%) patients, whereas PCI or CABG could have been equally selected in 31 (54.4%) patients (Figure 1). Conclusions According to the SYNTAX Score 2020 there was a strict observance of the CABG treatment recommendation in the first 57 consecutive patients with 3VD or LMCAD, screened on site in the FAST TRACK CABG trial. The more lenient selection criteria derived from the contemporary regitry will have to be tested propectively. Application of artificial intelligence with expanded collection of baseline characteristics, scientific endorsement and regulatory enforcement as well as further prospective evaluation are the challenges of future decision-making scores, that should be ultimately shared with the patients. Funding Acknowledgement Type of funding sources: None.
Restenosis after coronary angioplasty is the single complication that most limits this revascularization procedure in clinical practice. The process is largely unpredictable and the lesion-related factors predisposing to restenosis are poorly understood, with little consensus in published reports. In this study using detailed quantitative angiographic measurements to assess 490 lesions, the simple lesion characteristics associated with restenosis were defined and the relation to the restenosis process documented. Restenosis was defined as an absolute deterioration in the minimal lumen diameter by ≥ 0.72 mm, a criterion based on the 95% confidence intervals for repeat angiographic measurements. This was chosen in an attempt to separate spurious changes due to a poor angiographic result and the variability of angiographic measurements from significant changes due to the restenosis process. The principal determinants of restenosis were found to be a large improvement in the minimal lumen diameter at the time of dilation (1.13 mm for the restenosis group compared with 0.86 mm for the no restenosis group [p < 0.0001]) and an optimal postangioplasty result (minimal lumen diameter 2.28 mm in the restenosis group compared with 2.05 mm [p < 0.001] in the no restenosis group, corresponding to a 25% and a 30% diameter stenosis, respectively [p < 0.0001]). These observations reported for the first time suggest that the distinction needs to be made between a “clinical restenosis” of ≥ 50% diameter stenosis and the “restenosis process” as measured by the absolute changes occurring during and after angioplasty. They lend support to the hypothesis that the degree of mechanical stretch produced by the dilating balloon on the vessel wall may be important in stimulating the restenosis process. This is in contradiction to deductions obtained if restenosis is based on “clinical restenosis,” which suggests that restenosis is associated primarily with a poor angioplasty result. More important, it indicates that there is potential for misinterpreting the results of restenosis studies if the observations are based solely on conventional restenosis criteria without knowledge of the absolute changes occurring during and after the angioplasty procedure.
Background The purpose of this study was to identify biological risk factors for restenosis after PTCA, in order to predict the long-term outcome of PTCA before treatment. Methods and Results To investigate whether blood granulocytes and monocytes could determine luminal renarrowing after PTCA, several characteristics of these phagocytes were assessed before angioplasty in 32 patients who underwent PTCA of one coronary artery and who had repeat angiograms at six months follow-up. The plasma levels 1L-1β, TNF-α, IL-6, fibrinogen, C-reactive protein and LP(a) before angioplasty were assessed as well. We found that the expression of the membrane antigens CD64, CD66 and CD67 by granulocytes was inversely associated with the luminal renarrowing normalized for vessel size (relative loss) at six months after PTCA. while the production of IL-1β by stimulated monocytes was positively associated with the relative loss. Next. these univariate predictors were corrected for the established clinical risk factors, dilation of the LAD, current smoking and angina class. Multiple linear regression analysis showed that luminal renarrowing could be predicted reliably (R2 =0.65; P<0.0001) in this patients group on the basis of the vessel dilated and only two biological risk factors that reflect the activation status of blood phagocytes, i.e., the expression of CD66 by granulocytes and the production of IL-lβ by stimulated monocytes. Conclusions The results of the present study indicate that activated blood granulocytes prevent luminal renarrowing after PTCA, while activated blood monocytes promote restenosis. To validate this new finding further study in an independent patients group is required.